Speedy EU Assessment On Cards For AZ’s Durvalumab

 
• By Maureen Kenny

AstraZeneca is hoping that when it files for approval in the EU of its PD-L1 blocker, Imfinzi (durvalumab), for Stage III lung cancer, it will be given accelerated assessment on the back of the PACIFIC data.

Business Accelerator Program
Durvalumab could benefit from accelerated assessment in the EU • Source: Shutterstock

More from Immuno-oncology

More from Anticancer